COMP <GO>
MDLN vs RMD // 10Y YIELD & FRED MACRO BETA
Medline Inc. (NASDAQ) VS. ResMed Inc. (NYSE) • 15-METRIC TALLY: MDLN 4
— RMD 8
▲ 10Y YIELD & FRED MACRO BETA LEADER: MDLN
LAST: $32.12 (+0.38%) • MKT CAP: $42.07B
macro-sensitivity
1.11
LAST: $229.94 (-9.05%) • MKT CAP: $35.56B
macro-sensitivity
0.93
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MDLN VS. RMD)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MDLN | RMD | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 59.40% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 8.20% | 22.90% | -14.70 | RMD | /roic <GO> |
| EV/EBITDA & P/E Valuation | 20.3x | 19.9x | +0.40 | RMD | /valuation <GO> |
| Free Cash Flow Yield | 3.08% | 4.67% | -1.59 | RMD | /fcf-yield <GO> |
| Operating Margin | 7.80% | 32.70% | -24.90 | RMD | /operating-margins <GO> |
| Net Profit Margin | 68.00% | 27.20% | +40.80 | MDLN | /net-margins <GO> |
| Revenue Growth (YoY) | 11.50% | 9.80% | +1.70 | MDLN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.87% | -0.87 | RMD | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.50 | 12.49 | -9.99 | RMD | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 9/9 | -4.00 | RMD | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 30.9 | 60.1 | -29.20 | RMD | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | 1.11 | 0.93 | +0.18 | MDLN | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 23.6x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $42.07B | $35.56B | $6.51B | MDLN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MDLN REV | RMD REV | MDLN GROSS % | RMD GROSS % | MDLN FCF | RMD FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $28.43B | $5.15B | 26.4% | 59.4% | $1.30B | $1.66B |
| FY 2024 | $25.51B | $4.69B | 27.3% | 56.7% | $1.42B | $1.30B |
| FY 2023 | $23.23B | $4.22B | — | — | $639.6M | $503.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MDLN // BETA 1.11
RMD // BETA 0.93